Drug discovery is a complex and costly process, often resulting in many potential medications failing to progress through clinical trials. The primary reason for this is unforeseen toxicity issues, leading to significant waste of resources and the potential loss of life-saving drugs from the market. Conventional testing methods lack detail, and animal models frequently fail to accurately represent human responses to drugs. Organ-on-a-Chip (OOC) technology addresses these challenges by providing a more precise and efficient platform for evaluating drug safety.
A key issue in current drug discovery is the high failure rate, with up to 30% of drugs ceasing clinical trials due to toxicity concerns. OOC models are specifically designed to overcome this issue, offering a more accurate representation of human organs and the early detection of potential toxicity issues during the drug development phase. This enhanced understanding can save time, money, and resources, ultimately leading to a higher rate of success in drug development.
OOC models excel in evaluating drug-induced liver injury (DILI), a significant factor in drug trial failures. The PhysioMimix OOC microphysiological systems are specifically designed to assess DILI, utilizing a Liver-on-a-Chip model with human liver cells to identify potential toxicity. This model aids in identifying different types of liver injury and provides crucial endpoint measurements for analysis.
Furthermore, OOC technology is invaluable in testing new drug modalities with human-specific mechanisms of action, particularly in relation to the immune system. By offering a comprehensive assessment of a drug’s safety profile, OOC models can more accurately predict human immune system activation compared to traditional methods.
It is important to note that OOC technology is not intended to replace existing testing methods but rather to complement them. Each method has its limitations, and OOC models are most effective when used alongside other tests. This integrated approach can lead to a more precise and efficient testing process, with a reduced reliance on animal testing.
Given the unsustainable cost and complexity of drug discovery, OOC technology presents an opportunity for a more efficient and successful process. Embracing this technology now can provide a competitive advantage, as regulatory bodies increasingly recognize the value of OOC data. Utilizing OOC models represents a commitment to a future of safer and more effective medications.
For a more in-depth understanding of how OOC technology is shaping the future of drug discovery, the full article is available at https://bit.ly/3JhIDXJ.